1. Home
  2. NVNI vs BFRI Comparison

NVNI vs BFRI Comparison

Compare NVNI & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVNI
  • BFRI
  • Stock Information
  • Founded
  • NVNI 2019
  • BFRI 1997
  • Country
  • NVNI Brazil
  • BFRI United States
  • Employees
  • NVNI N/A
  • BFRI N/A
  • Industry
  • NVNI
  • BFRI Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVNI
  • BFRI Health Care
  • Exchange
  • NVNI Nasdaq
  • BFRI Nasdaq
  • Market Cap
  • NVNI 10.4M
  • BFRI 8.7M
  • IPO Year
  • NVNI N/A
  • BFRI 2021
  • Fundamental
  • Price
  • NVNI $0.22
  • BFRI $0.78
  • Analyst Decision
  • NVNI
  • BFRI Strong Buy
  • Analyst Count
  • NVNI 0
  • BFRI 1
  • Target Price
  • NVNI N/A
  • BFRI $7.00
  • AVG Volume (30 Days)
  • NVNI 18.1M
  • BFRI 90.9K
  • Earning Date
  • NVNI 05-07-2025
  • BFRI 03-21-2025
  • Dividend Yield
  • NVNI N/A
  • BFRI N/A
  • EPS Growth
  • NVNI N/A
  • BFRI N/A
  • EPS
  • NVNI N/A
  • BFRI N/A
  • Revenue
  • NVNI $23,558,620.00
  • BFRI $37,321,000.00
  • Revenue This Year
  • NVNI $25.91
  • BFRI $28.62
  • Revenue Next Year
  • NVNI $17.52
  • BFRI $27.07
  • P/E Ratio
  • NVNI N/A
  • BFRI N/A
  • Revenue Growth
  • NVNI 38.59
  • BFRI 9.54
  • 52 Week Low
  • NVNI $0.17
  • BFRI $0.65
  • 52 Week High
  • NVNI $12.19
  • BFRI $2.43
  • Technical
  • Relative Strength Index (RSI)
  • NVNI 28.69
  • BFRI 33.18
  • Support Level
  • NVNI $0.20
  • BFRI $0.77
  • Resistance Level
  • NVNI $0.22
  • BFRI $0.96
  • Average True Range (ATR)
  • NVNI 0.03
  • BFRI 0.08
  • MACD
  • NVNI 0.11
  • BFRI -0.01
  • Stochastic Oscillator
  • NVNI 25.00
  • BFRI 2.70

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About BFRI Biofrontera Inc.

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.

Share on Social Networks: